Jack Pasini
Directeur/Bestuurslid bij Oligomerix, Inc.
Profiel
Jack Pasini is currently the Director & Chief Commercial Officer at Oligomerix, Inc. He previously worked as the Vice President-Infectious Diseases & Allergy at Pfizer Inc. Mr. Pasini holds an MBA from Fairleigh Dickinson University and an undergraduate degree from Merrimack College.
Actieve functies van Jack Pasini
| Bedrijven | Functie | Begin |
|---|---|---|
Oligomerix, Inc.
 Oligomerix, Inc. Drugstore ChainsRetail Trade Oligomerix, Inc. develops novel therapeutics and diagnostic assays for alzheimer diseases. It is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers. The firm's platform is based on small neurotoxic aggregates of proteins such as tau oligomers, an important target for AD and other tauopathies characterized by the progressive accumulation of tau aggregates. The company was founded by James G. Moe, Eliot J. Davidowitz, Ishita Chatterjee and Pedro M. Rojas in 2006 and is headquartered in New York, NY. | Directeur/Bestuurslid | 18-10-2010 |
Eerdere bekende functies van Jack Pasini
| Bedrijven | Functie | Einde |
|---|---|---|
| PFIZER, INC. | Corporate Officer/Principal | - |
Opleiding van Jack Pasini
| Merrimack College | Undergraduate Degree |
| Fairleigh Dickinson University | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| PFIZER, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Oligomerix, Inc.
Oligomerix, Inc. Drugstore ChainsRetail Trade Oligomerix, Inc. develops novel therapeutics and diagnostic assays for alzheimer diseases. It is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers. The firm's platform is based on small neurotoxic aggregates of proteins such as tau oligomers, an important target for AD and other tauopathies characterized by the progressive accumulation of tau aggregates. The company was founded by James G. Moe, Eliot J. Davidowitz, Ishita Chatterjee and Pedro M. Rojas in 2006 and is headquartered in New York, NY. | Retail Trade |